Research Article

Urinary Tract Infections in the First 6 Months after Renal Transplantation

Table 1

Patients’ characteristics.

Pt characteristicsTotalNo UTIUTI
27997182

Age43.4 ± 15.842.1 ± 15.645.8 ± 16.00.063
Gender
 Male16512837<0.001
59.10%70.30%38.10%
 Female1145460
40.90%29.70%61.90%

Diabetes mellitus9559360.507
34.10%32.40%37.10%
 Type I251960.099
26.60%32.80%16.70%
 Type II693930
73.40%67.20%83.30%

Donor type
 Deceased5534210.636
19.70%18.70%21.60%
 Living22414876
80.30%81.30%78.40%

Transplant abroad219120.032
7.50%4.90%12.40%

Pretransplant residual urine volume
24-hour urine volume
 Anuria6845230.805
24.40%24.70%23.70%
 Oliguria412912
14.70%15.90%12.40%
 Normal623824
22.20%20.90%24.70%

Preexisting urological abnormalities
Treated urethral stricture11920.340
3.90%4.90%2.10%
Vesicoureteral reflux ( VUR)7340.242
2.50%1.60%4.10%
Neurogenic bladder10370.023
3.60%1.60%7.20%

Foley catheter
Foley catheter removal time5.8 ± 2.05.7 ± 1.96.1 ± 2.30.120
Foley catheter reinsertion6330.668
2.20%1.70%3.10%

Serum creatinine in mmol/L
At 1 month103.7 ± 47.2105.1 ± 49.1101.0 ± 43.50.493
At 6 months99.0 ± 34.0100.4 ± 34.996.4 ± 32.40.352

Immunosuppression status
Induction therapy
 Basiliximab10772350.607
38.40%39.60%36.10%
 Thymoglobulin (ATG)17211062
61.60%60.40%63.90%
Rejection within 6 months221481
7.90%7.70%8.20%
Detected polyoma viremia191450.467
6.80%7.70%5.20%

UTI antibiotic prophylaxis
TMP/SMX double strength + norfloxacin7049210.385
25.10%26.90%21.60%
TMP/SMX single strength20913376
74.90%73.10%78.40%

Stent removal time (days)
Stent removal time (days)35.3 ± 28.034.2 ± 28.737.3 ± 26.80.376

Urgent stent removal due to non-UTI reasons
Stent migration to urethra651<0.011
2.1%1.8%0.30%

Postrenal transplant surgical complications
Urine leak3120.554
1.10%0.50%2.10%
Ureteral stenosis6330.668
2.20%1.60%3.10%

Continuous data were reported as (mean ± SD), and categorical data were reported as numbers and percentages. Detected polyoma viremia >50 copies/ml.